Personal Home Page

http://www.aecom.yu.edu/home/faculty/profile.asp?id=3478&O=1

Articles in Scholarly Journals [Incomplete List]

1. The immunoglobulin constant region contributes to affinity and specificity
   Trends in Immunology, vol. 29, no. 2, pp. 91–97, 2008
2. Fungal killing by mammalian phagocytic cells
   Current Opinion in Microbiology, 2008
3. Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1
   Medical Mycology, vol. 46, no. 2, pp. 153–162, 2008
4. Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum
   Expert Review of Vaccines, vol. 7, no. 1, pp. 55–74, 2008
5. Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches
   Expert Review of Anti-infective Therapy, vol. 5, no. 3, pp. 461–474, 2007
6. Exploiting Amoeboid and Non-Vertebrate Animal Model Systems to Study the Virulence of Human Pathogenic Fungi
   PLoS Pathogens, vol. 3, no. 7, p. e101, 2007
7. Comparative Evaluation of Capsular Polysaccharide-Specific IgM and IgG Antibodies and F(ab')2 and Fab Fragments as Delivery Vehicles for Radioimmunotherapy of Fungal Infection
   Clinical Cancer Research, vol. 13, no. 18, pp. 5629s–5635s, 2007
8. Targeting host cells harbouring viruses with radiolabeled antibodies
   Expert Opinion on Biological Therapy, vol. 7, no. 5, pp. 595–597, 2007
9. Cryptococcus neoformans Biofilm Formation Depends on Surface Support and Carbon Source and Reduces Fungal Cell Susceptibility to Heat, Cold, and UV Light
   Applied and Environmental Microbiology, vol. 73, no. 14, pp. 4592–4601, 2007
10. Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar
    FEMS Yeast Research, vol. 7, no. 2, pp. 339–350, 2007
11. Dependence of Macrophage Phagocytic Efficacy on Antibody Concentration
    Infection and Immunity, vol. 75, no. 4, pp. 1904–1915, 2007
12. Galactoxylomannan Does Not Exhibit Cross-Reactivity in the Platelia Aspergillus Enzyme Immunoassay
    Clinical and Vaccine Immunology, vol. 14, no. 5, pp. 624–627, 2007
13. Self-Aggregation of Cryptococcus neoformans Capsular Glucuronoxylomannan Is Dependent on Divalent Cations
    Eukaryotic Cell, vol. 6, no. 8, pp. 1400–1410, 2007
14. Accidental Virulence, Cryptic Pathogenesis, Martians, Lost Hosts, and the Pathogenicity of Environmental Microbes
    Eukaryotic Cell, vol. 6, no. 12, pp. 2169–2174, 2007
15. Binding of Glucuronoxylomannan to the CD14 Receptor in Human A549 Alveolar Cells Induces Interleukin-8 Production
    Clinical and Vaccine Immunology, vol. 14, no. 1, pp. 94–98, 2007
16. Capsule Structural Heterogeneity and Antigenic Variation in Cryptococcus neoformans
    Eukaryotic Cell, vol. 6, no. 8, pp. 1464–1473, 2007
17. Antibody-Mediated Protection through Cross-Reactivity Introduces a Fungal Heresy into Immunological Dogma
    Infection and Immunity, vol. 75, no. 11, pp. 5074–5078, 2007
18. Binding of the Wheat Germ Lectin to Cryptococcus neoformans Suggests an Association of Chitinlike Structures with Yeast Budding and Capsular Glucuronoxylomannan
    Eukaryotic Cell, vol. 7, no. 4, pp. 602–609, 2007
19. Extracellular Vesicles Produced by Cryptococcus neoformans Contain Protein Components Associated with Virulence
    Eukaryotic Cell, vol. 7, no. 1, pp. 58–67, 2007
20. The Relative Susceptibility of Mouse Strains to Pulmonary Cryptococcus neoformans Infection Is Associated with Pleiotropic Differences in the Immune Response
    Infection and Immunity, vol. 75, no. 6, pp. 2729–2739, 2007
21. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages
    BMC Immunology, vol. 8, no. 1, p. 16, 2007
22. Growth and Pigment Production on D-Tryptophan Medium by Cryptococcus gattii, Cryptococcus neoformans, and Candida albicans
    Journal of Clinical Microbiology, vol. 46, no. 1, pp. 255–264, 2007
23. The Immunoglobulin Heavy Chain Constant Region Affects Kinetic and Thermodynamic Parameters of Antibody Variable Region Interactions with Antigen
    Journal of Biological Chemistry, vol. 282, no. 18, pp. 13917–13927, 2007
24. Targeting the Virus with Radioimmunotherapy in Virus-Associated Cancers
    Cancer Biotherapy & Radiopharmaceuticals, vol. 22, no. 3, pp. 303–308, 2007
25. SEROLOGIC EVIDENCE FOR REGIONAL DIFFERENCES IN PEDIATRIC CRYPTOCOCCAL INFECTION
    The Pediatric Infectious Disease Journal, vol. 26, no. 6, pp. 549–551, 2007
26. Cryptococcus neoformans laccase catalyses melanin synthesis from both D- and L-DOPA
    Microbiology, vol. 153, no. 12, pp. 3954–3962, 2007
27. Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51
    Tuberculosis, vol. 87, no. 6, pp. 489–497, 2007
28. Determinants of virulence in the pathogenic fungi
    Fungal Biology Reviews, vol. 21, no. 4, pp. 130–132, 2007
29. Coccidioides posadasii produces melanin in vitro and during infection
    Fungal Genetics and Biology, vol. 44, no. 6, pp. 517–520, 2007
30. Caspofungin reduces the incidence of fungal contamination in cell culture
    Mycopathologia, vol. 164, no. 6, pp. 279–286, 2007
31. The volume and hydration of the Cryptococcus neoformans polysaccharide capsule
    Fungal Genetics and Biology, vol. 44, no. 3, pp. 180–186, 2007
32. Efficacy of voriconazole in experimental Cryptococcus neoformans infection
    Mycopathologia, vol. 162, no. 2, pp. 111–114, 2006
33. Polysaccharide-containing conjugate vaccines for fungal diseases
    Trends in Molecular Medicine, vol. 12, no. 1, pp. 6–9, 2006
34. The capsular dynamics of Cryptococcus neoformans
    Trends in Microbiology, 2006
35. Phagosome Extrusion and Host-Cell Survival after Cryptococcus neoformans Phagocytosis by Macrophages
    Current Biology, vol. 16, no. 21, pp. 2161–2165, 2006
36. Structural and functional characterization of glycosylation in an immunoglobulin G1 to Cryptococcus neoformans glucuronoxylomannan
    Molecular Immunology, vol. 43, no. 7, pp. 987–998, 2006
37. Melanin in the dimorphic fungal pathogen Paracoccidioides brasiliensis: effects on phagocytosis, intracellular resistance and drug susceptibility
    Microbes and Infection, vol. 8, no. 1, pp. 197–205, 2006
38. Immunomodulators as an antimicrobial tool
    Current Opinion in Microbiology, vol. 9, no. 5, pp. 489–495, 2006
39. Radiolabeled Melanin-Binding Peptides Are Safe and Effective in Treatment of Human Pigmented Melanoma in a Mouse Model of Disease
    Cancer Biotherapy Radiopharmaceuticals, vol. 21, no. 2, pp. 117–129, 2006
40. Equatorial ring-like channels in the Cryptococcus neoformans polysaccharide capsule
    FEMS Yeast Research, vol. 6, no. 4, pp. 662–666, 2006
41. Impact of Melanin on Microbial Virulence and Clinical Resistance to Antimicrobial Compounds
    Antimicrobial Agents and Chemotherapy, vol. 50, no. 11, pp. 3519–3528, 2006
42. Susceptibility of Cryptococcus neoformans Biofilms to Antifungal Agents In Vitro
    Antimicrobial Agents and Chemotherapy, vol. 50, no. 3, pp. 1021–1033, 2006
43. Cryptococcus neoformans Can Utilize the Bacterial Melanin Precursor Homogentisic Acid for Fungal Melanogenesis
    Applied and Environmental Microbiology, vol. 73, no. 2, pp. 615–621, 2006
44. Synthetic Consolidants Attacked by Melanin-Producing Fungi: Case Study of the Biodeterioration of Milan (Italy) Cathedral Marble Treated with Acrylics
    Applied and Environmental Microbiology, vol. 73, no. 1, pp. 271–277, 2006
45. Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt
    Clinical Infectious Diseases, vol. 43, no. 8, pp. 1031–1039, 2006
46. Update: Renaissance of Targeting Molecules for Melanoma
    Cancer Biotherapy & Radiopharmaceuticals, vol. 21, no. 6, pp. 545–552, 2006
47. Enhanced Allergic Inflammation and Airway Responsiveness in Rats with Chronic Cryptococcus neoformans Infection: Potential Role for Fungal Pulmonary Infection in the Pathogenesis of Asthma
    The Journal of Infectious Diseases, vol. 193, no. 8, pp. 1178–1186, 2006
48. The Third Age of Antimicrobial Therapy
    Clinical Infectious Diseases, vol. 42, no. 10, pp. 1414–1416, 2006
49. Interaction of Radiolabeled Antibodies with Fungal Cells and Components of the Immune System In Vitro and during Radioimmunotherapy for Experimental Fungal Infection
    The Journal of Infectious Diseases, vol. 193, no. 10, pp. 1427–1436, 2006
50. Specific Antibody to Cryptococcus neoformans Glucurunoxylomannan Antagonizes Antifungal Drug Action against Cryptococcal Biofilms In Vitro
    The Journal of Infectious Diseases, vol. 194, no. 2, pp. 261–266, 2006
51. The weapon potential of human pathogenic fungi
    Medical Mycology, vol. 44, no. 8, pp. 689–696, 2006
52. Cryptococcus neoformans Cells in Biofilms Are Less Susceptible than Planktonic Cells to Antimicrobial Molecules Produced by the Innate Immune System
    Infection and Immunity, vol. 74, no. 11, pp. 6118–6123, 2006
53. Radial Mass Density, Charge, and Epitope Distribution in the Cryptococcus neoformans Capsule
    Eukaryotic Cell, vol. 6, no. 1, pp. 95–109, 2006
54. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8
    Cellular Microbiology, vol. 8, no. 2, pp. 267–275, 2006
55. A Monoclonal Antibody to Bacillus anthracis Protective Antigen Defines a Neutralizing Epitope in Domain 1
    Infection and Immunity, vol. 74, no. 7, pp. 4149–4156, 2006
56. Vesicular Polysaccharide Export in Cryptococcus neoformans Is a Eukaryotic Solution to the Problem of Fungal Trans-Cell Wall Transport
    Eukaryotic Cell, vol. 6, no. 1, pp. 48–59, 2006
57. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance
    Cellular Microbiology, vol. 8, no. 12, pp. 1862–1876, 2006
58. Induction by Klebsiella aerogenes of a Melanin-Like Pigment in Cryptococcus neoformans
    Applied and Environmental Microbiology, vol. 72, no. 2, pp. 1542–1550, 2006
59. The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding
    Molecular Microbiology, vol. 59, no. 1, pp. 67–83, 2006
60. Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis
    Cellular Microbiology, vol. 8, no. 11, pp. 1730–1739, 2006
61. Targeted Killing of Virally Infected Cells by Radiolabeled Antibodies to Viral Proteins
    PLoS Medicine, vol. 3, no. 11, p. e427, 2006
62. Estimating the Relative Contributions of Virulence Factors for Pathogenic Microbes
    Infection and Immunity, vol. 74, no. 3, pp. 1500–1504, 2006
63. BMC Microbiology, vol. 6, no. 1, p. 55, 2006
64. Dual Infections with Pigmented and Albino Strains of Cryptococcus neoformans in Patients with or without Human Immunodeficiency Virus Infection in India
    Journal of Clinical Microbiology, vol. 43, no. 9, pp. 4766–4772, 2005
65. Melanin as a potential target for radionuclide therapy of metastatic melanoma
    Future Oncology, vol. 1, no. 4, pp. 541–549, 2005
66. The potential of antibody-mediated immunity in the defence against biological weapons
    Expert Opinion on Biological Therapy, vol. 5, no. 10, pp. 1359–1372, 2005
67. Insights into Mechanisms of Antibody-Mediated Immunity from Studies with Cryptococcus neoformans
    Current Molecular Medicine, vol. 5, no. 4, pp. 421–433, 2005
68. Coping with Multiple Virulence Factors: Which Is Most Important?
    PLoS Pathogens, vol. 1, no. 4, p. e40, 2005
69. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases
    Expert Opinion on Drug Delivery, vol. 2, no. 6, pp. 1075–1084, 2005
70. Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis
    Antimicrobial Agents and Chemotherapy, vol. 49, no. 3, pp. 952–958, 2005